公开(公告)号：US20130315865A1

公开(公告)日：2013-11-28

申请号：US13950584

申请日：2013-07-25

Applicant: PFIZER INC.

Inventor： Aranapakam Mudumbai VENKATESAN ,  Zecheng CHEN ,  Christoph Martin DEHNHARDT ,  Osvaldo DOS SANTOS ,  Efren Guillermo DELOS SANTOS ,  Arie ZASK ,  Jeroen Cunera VERHEIJEN ,  Joshua Aaron KAPLAN ,  David James RICHARD ,  Semiramis AYRAL-KALOUSTIAN ,  Tarek Suhayl MANSOUR ,  Ariamala GOPALSAMY ,  Kevin Joseph CURRAN ,  Mengxiao SHI

IPC: A61K31/5377 ,  A61K45/06 ,  C07D413/14

CPC classification number: C07D401/12 ,  A61K31/5377 ,  A61K45/06 ,  C07D251/18 ,  C07D401/04 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D413/04 ,  C07D413/14 ,  C07D451/06 ,  C07D453/02 ,  C07D491/113 ,  C07D498/08

Abstract: Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.

公开(公告)号：US20130109670A1

公开(公告)日：2013-05-02

申请号：US13718928

申请日：2012-12-18

Applicant: PFIZER INC.

Inventor： Aranapakam Mudumbai VENKATESAN ,  Zecheng CHEN ,  Christoph Martin DEHNHARDT ,  Osvaldo DOS SANTOS ,  Efren Guillermo DELOS SANTOS ,  Arie ZASK ,  Jeroen Cunera VERHEIJEN ,  Joshua Aaron KAPLAN ,  David James RICHARD ,  Semiramis AYRAL-KALOUSTIAN ,  Tarek Suhayl MANSOUR ,  Ariamala GOPALSAMY ,  Kevin Joseph CURRAN ,  Mengxiao SHI

IPC: C07D498/08 ,  C07D491/113 ,  C07D413/14

CPC classification number: C07D401/12 ,  A61K31/5377 ,  A61K45/06 ,  C07D251/18 ,  C07D401/04 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D413/04 ,  C07D413/14 ,  C07D451/06 ,  C07D453/02 ,  C07D491/113 ,  C07D498/08

Abstract: Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.

公开(公告)号：US20180230127A1

公开(公告)日：2018-08-16

申请号：US15751310

申请日：2016-07-29

Applicant: PFIZER INC.

Inventor： DAVID RANDOLPH ANDERSON ,  Kevin Joseph CURRAN ,  Lori Krim GAVRIN ,  Joel Adam GOLDBERG ,  Arthur LEE ,  Michael Dennis LOWE ,  Akshay Patny ,  Betsy Susan PIERCE ,  Eddine SAIAH ,  John David TRZUPEK

IPC: C07D401/12 ,  C07D211/94

CPC classification number: C07D401/12 ,  A61K31/437 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K2300/00 ,  C07D211/94 ,  C07D451/06

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds of Formula (Ia) are disclosed which are inhibitors of Interleukin-1 receptor associated kinase (IRAK4). Methods of treatment, methods of synthesis, and intermediates are also disclosed as defined in the specification.